Fhl-1は,肺高血圧における新しい重要なタンパク質である
Grazyna Kwapiszewska1, Malgorzata Wygrecka, Leigh M Marsh
1Med Klinik II, University of Giessen Lung Center, Klinik Strasse 36, 35392 Giessen, Germany. Grazyna.Kwapiszewska@uglc.de
Circulation
|August 30, 2008
まとめ
研究者らは,Fhl-1を肺高血圧 (PH) で上調される重要なタンパク質として特定しました. この発見は,PHの発達と,この重症な状態に対する潜在的な治療目標に関する新しい洞察を提供します.
科学分野:
- 心血管研究 循環器科の研究
- 肺内医学 肺内医学 肺内医学
- 分子生物学は分子生物学である.
背景:
- 肺高血圧 (PH) は,血管の再構築と右心不全によって特徴づけられる重症疾患です.
- PHに関連した血管再構築を駆動する分子機構は十分に理解されていません.
- 疾患の発症時の重要な要因を特定することは,PHを理解するために極めて重要です.
研究 の 目的:
- PHの初期段階における肺組織におけるタンパク質発現の変化をスクリーニングする.
- 低酸素誘発PHの発症に関与する重要な分子プレーヤーを特定する.
主な方法:
- 2Dポリアクリラミドゲル電泳とMALDI-TOF分析により,タンパク質の変化をスクリーニングする.
- タンパク質発現を確認するために,免疫ヒストキミストリー,ウエスタンブロット,およびqPCR.
- ヒト肺動脈の滑らかな筋肉細胞を用いた実験室内研究では,Fhl-1の機能を評価した.
主要な成果:
- 早期の低酸素誘発PHで変化した発現を持つ36のタンパク質を特定し,顕著に調節されたFhl-1を含む.
- 様々なPHモデル (低酸素症,モノクロタリン,SU5416) とヒトの異症性肺動脈高血圧におけるFhl-1アップレギュレーションが確認されています.
- Fhl-1が肺動脈の滑らかな筋肉細胞の移動と増殖を調節することを実証し,Talin1を相互作用するパートナーとして特定しました.
結論:
- Fhl-1は,PHの複数の形態で有意に調節される新しいタンパク質です.
- Fhl-1は,肺高血圧の病原化に役割を果たしています.
- Fhl-1は,PHと異症性肺動脈高血圧の潜在的な治療標的を表しています.
関連する概念動画
01:24Regulation of Angiogenesis and Blood Supply
2.9K
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
2.9K
01:18Hypertension and Regulation of Blood Pressure
3.8K
Hypertension, the most common cardiovascular disease, is diagnosed through repeated measurements of elevated blood pressure. Its risks, including damage to the kidney, heart, and brain, are directly proportional to blood pressure levels. Starting from 115/75 mm Hg, the risk of cardiovascular disease doubles with each increment of 20/10 mm Hg. The diagnosis relies on blood pressure measurements, not on patient symptoms, as hypertension is often asymptomatic until end-organ damage is imminent or...
3.8K
01:17Hormonal Regulation of Blood Pressure
7.8K
Endocrinal or hormonal intervention in the cardiovascular system is predominantly exerted by the catecholamines - epinephrine and norepinephrine, as well as a slew of hormones that interact with renal function to modulate blood volume.
Epinephrine and Norepinephrine
The adrenal medulla releases epinephrine and norepinephrine, catecholamines that enhance and extend the sympathetic or "fight or flight" physiological response. These hormones escalate heart rate and the force of contraction...
Epinephrine and Norepinephrine
The adrenal medulla releases epinephrine and norepinephrine, catecholamines that enhance and extend the sympathetic or "fight or flight" physiological response. These hormones escalate heart rate and the force of contraction...
7.8K
01:19Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
765
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
765
01:29Heart Failure II: Pathophysiology
1.9K
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
1.9K
01:30Heart Failure V: Medical Management
626
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
626